| Nov 9 |
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight
|
| Nov 7 |
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
| Nov 7 |
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
Revolution Medicines, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 6 |
Revolution Medicines GAAP EPS of -$0.94 misses by $0.04
|
| Nov 6 |
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
|
| Nov 5 |
Revolution Medicines to Participate in Upcoming Investor Conferences
|
| Oct 30 |
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
|
| Oct 25 |
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
|
| Oct 23 |
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
|
